Healthcare Industry News: abdominal aortic aneurysm
News Release - June 15, 2009
Talent Stent Graft Shows Durable Performance in Patients with Abdominal Aortic AneurysmsFive-Year Results from U.S. Clinical Trial Presented at 2009 Vascular Annual Meeting
MINNEAPOLIS--(HSMN NewsFeed)--Through five years following initial implantation in an FDA-approved study, the Talent Abdominal Stent Graft from Medtronic, Inc. (NYSE: MDT ), demonstrated durable safety and effectiveness in patients with abdominal aortic aneurysms, despite having included patients with more challenging anatomies than comparable trials of similar medical devices.
The five-year results from the Talent AAA U.S. IDE (investigational device exemption) study were presented on Friday, June 12th at the clinical trial session of the Society for Vascular Surgery (SVS). The study results support the long-term safety and efficacy of the Talent Abdominal Stent Graft in the minimally-invasive treatment of abdominal aortic aneurysms. Earlier data from the study contributed to the original FDA approval for the device in April 2008. These latest data constitute the final results of the study, which involved 166 patients enrolled between February 2002 and April 2003 at 13 clinical research sites in the United States.
“In a population with more challenging anatomical characteristics than in other clinical trials of similar technologies for endovascular repair of abdominal aortic aneurysms, the Talent Stent Graft System compared favorably with open repair through one year,” said Dr. Luis Sanchez of Washington University Hospital in St. Louis, who shared the findings with hundreds of physicians attending the 2009 Vascular Annual Meeting. “More importantly, the Medtronic device also provided sustained protection from aneurysm-related mortality through five years, with minimal reinterventions.”
The study’s primary safety endpoint compared a composite of major adverse events (MAE) to an historical control of 243 patients who underwent conventional open surgical repair of their aneurysm. Freedom from MAE at 30 days was 89.2 percent in the Talent AAA group and 44 percent in the open surgical repair group.
The effectiveness endpoint assessed successful aneurysm treatment, defined as technical success with device placement, as well as freedom from aneurysm growth greater than 5 mm and freedom from Type I or III endoleak, at one year. Successful aneurysm treatment at 12 months was obtained in 90.2 percent of the Talent AAA study population.
Other highlights of the five-year outcomes include a 96.5 percent freedom from aneurysm-related death, freedom from AAA rupture of 98.2 percent, freedom from conversion to open repair of 99.1 percent, and freedom from migration of 97.7 percent.
“At five years, not only were outcomes related to aneurysm-related mortality, conversion to surgery and rupture satisfactory, but the incidence of device migration was only 2.3 percent,” said principal investigator Dr. Frank Criado of Union Memorial Hospital in Baltimore.
Importantly for interpreting the results, this study enrolled a significant number of patients with challenging AAA morphology who would have been excluded from IDE trials of other stent graft products because of stricter inclusion criteria in those trials and limited device size offerings.
The Talent Abdominal Stent Graft expands the applicability of endovascular aortic repair (EVAR), enabling more patients to benefit from a less invasive alternative to open surgical repair. Talent AAA is the only stent graft approved by the FDA for use in the treatment of abdominal aortic aneurysms with proximal necks (“landing zones”) as short as 10 mm. The Talent Abdominal Stent Graft System has been used internationally since 1997 to repair the aortic aneurysms of approximately 50,000 patients.
A pioneer of EVAR, Medtronic has been an innovator and leader in the stent graft industry since the 1990s, with more than 150,000 patients treated with its devices. The company offers the broadest portfolio of stent grafts. Among these are the Talent Abdominal and Thoracic Stent Grafts in the United States, as well as the Endurant® Abdominal and the Valiant® Thoracic Stent Grafts outside the United States.
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health and extending life for millions of people around the world.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s Annual Report on Form 10-K for the year ended April 25, 2008. Actual results may differ materially from anticipated results.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.